MitraClip Valve Repair for Mitral Valve Regurgitation
Beaumont was the first hospital in Metro Detroit to treat patients in a clinical study evaluating the MitraClip system to repair the mitral valve without heart surgery. The results of the clinical data that studied the MitraClip implant demonstrated safety,
reduction of mitral valve regurgitation, rapid recovery, improvement in symptoms and reduction in hospitalizations for heart failure.
In October 2013, the Food and Drug Administration (FDA) approved the use of the MitraClip for trans-cather edge
to edge repair (TEER) in patients with primary mitral valve regurgitation (MR) who are not good candidates for surgery. Beaumont was the first hospital in Michigan to implant the commercially approved MitraClip for this indication.
multi-center trial research demonstrated the success of TEER using MitraClip for patients diagnosed with moderate-to-severe or severe MR secondary to systolic heart failure (enlarged, weakened heart) when medications alone are inadequate. In March 2019,
FDA approved MitraClip for this indication. After Medicare expanded its criteria for coverage in January 2021, we have been able to offer TEER using MitraClip to appropriate patients with secondary MR.